Nasus Pharma is a clinical-stage pharmaceutical company developing proprietary intranasal powder product candidates for emergency and acute care settings, with lead programs in intranasal epinephrine for anaphylaxis treatment and intranasal naloxone for opioid overdose reversal. The company's proprietary delivery platform enables rapid, non-invasive drug administration and targets large unmet medical needs in emergency treatment markets where established competitors like EpiPen and Narcan already operate. Nasus anticipates generating revenue only upon achieving regulatory approval and successful commercialization of its product candidates, planning to pursue FDA approval via the 505(b)(2) pathway while expanding internationally, with near-term capital requirements focused on completing clinical trials, manufacturing scale-up, regulatory submissions, and building sales and distribution infrastructure.